pH-labile artificial natural killer cells for overcoming tumor drug resistance

Waldhauer, 2008, Oncogene, 27, 5932, 10.1038/onc.2008.267 Vivier, 2012, Nat. Rev. Immunol., 12, 239, 10.1038/nri3174 Jhunjhunwala, 2021, Nat. Rev. Cancer, 21, 298, 10.1038/s41568-021-00339-z Ben-Shmuel, 2020, Front. Immunol., 11 Liu, 2021, J. Hematol. Oncol., 14 Cursons, 2019, Cancer Immunol. Res., 7, 1162, 10.1158/2326-6066.CIR-18-0500 Huntington, 2020, Nat. Rev. Cancer, 20, 437, 10.1038/s41568-020-0272-z Bald, 2020, Nat. Immunol., 21, 835, 10.1038/s41590-020-0728-z Liu, 2020, New Engl. J. Med., 382, 545, 10.1056/NEJMoa1910607 Xie, 2020, EBioMedicine, 59 Gang, 2020, Blood, 136, 2308, 10.1182/blood.2020006619 Zou, 2019, Adv. Mater., 31 Brodbeck, 2014, Mol. Cancer, 13 Johansson, 2006, J. Immunol., 177, 7923, 10.4049/jimmunol.177.11.7923 Housman, 2014, Cancers, 6, 1769, 10.3390/cancers6031769 Perekalin, 2015, Chem. Eur. J., 21, 4923, 10.1002/chem.201406510 Gimenez, 2015, Langmuir, 31, 3146, 10.1021/la504293q Li, 2017, Chem. Sci., 8, 7675, 10.1039/C7SC03217J Lee, 2019, J. Immunother. Cancer, 7, 147, 10.1186/s40425-019-0610-4 Lv, 2021, Biomaterials, 277, 10.1016/j.biomaterials.2021.121076 Shen, 2014, Nano Lett., 14, 923, 10.1021/nl404316v Shen, 2015, ACS Appl. Mater. Interfaces, 7, 17450, 10.1021/acsami.5b04992 Kim, 2020, Nano Converg., 7, 30, 10.1186/s40580-020-00241-8 Zeng, 2017, Adv. Funct. Mater., 27, 1605985, 10.1002/adfm.201605985 Li, 2022, Acta Pharm. Sin. B, 12, 107, 10.1016/j.apsb.2021.05.031 Li, 2021, J. Control. Release, 338, 719, 10.1016/j.jconrel.2021.09.005 Shi, 2020, Chin. Chem. Lett., 31, 1345, 10.1016/j.cclet.2020.03.001 Ou, 2022, J. Control. Release, 345, 755, 10.1016/j.jconrel.2022.03.059 Cheng, 2017, Adv. Funct. Mater., 27, 10.1002/adfm.201704135